Post by
Alex1726 on Jan 20, 2024 9:00pm
Macimorelin
Approved Macimorelin to treat AGHD and CGHD in advanced phase III showing very poromising potential to reach market is to my humble opinion by now a more de-risked asset than PGX could be.
We do not know what will happen with Pressurized Gas eXpanded Technology (PGX).
If PGX does not deliver goods results, CZO does not worth much , it is a real good familly business , and developping the technology might be much more cap-ex than what was known, anyway we"ll never know the real issues with Gagnon.
Comment by
Alex1726 on Jan 20, 2024 9:11pm
Macimorelin could be a very valuable asset , maybe more than PGX. Make your own opinion and share it. https://www.evaluate.com/vantage/articles/news/deals/flipping-win-strongbridge-biopharma